Visit https://www.peervoice.com/UWX860 to view the entire programme with slides. After completing “Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know”, participants will be able to: Explain the role of GLP-1 RAs in stroke prevention in type 2 diabetes (T2DM); Evaluate the cardiovascular outcomes data for GLP-1 RAs in terms of stroke prevention in patients with T2DM; and Apply optimal treatment plans for reducing the risk of stroke in patients with T2DM.